GO:0046007 negative regulation of activated T cell proliferation: Immune Tolerance Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046007 describes any biological process that stops, prevents, or reduces the rate or extent of activated T cell proliferation, a cornerstone of peripheral immune tolerance and immune homeostasis.
• Negative regulation of activated T cell proliferation is enforced by multiple layers: coinhibitory receptors such as CTLA4, intracellular phosphatases such as HePTP, and serine/threonine kinases such as GSK-3.
• Calcium/NFAT signaling is a central node integrating TCR and costimulatory signals; its modulation directly controls whether activated T cells expand or arrest.
• Tetraspanin CD53 stabilizes CD45RO and regulates its mobility and function, thereby tuning TCR signal strength and T cell proliferative responses.
• Dysregulation of this process underlies autoimmunity, transplant rejection, and impaired antitumor immunity, making it a high-value target for therapeutic and CRISPR-based research.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal dissection of genes that negatively regulate activated T cell proliferation.
Description
Negative regulation of activated T cell proliferation (GO:0046007) is a biological process that stops, prevents, or reduces the rate or extent of proliferation of T cells that have already been activated through their antigen receptor. This process is essential for limiting collateral tissue damage during infection, maintaining peripheral tolerance, and preventing autoimmunity. Researchers study it because the balance between activating and inhibitory signals determines the outcome of immune responses, and because therapeutic manipulation of this balance is central to cancer immunotherapy, transplantation, and autoimmune disease treatment.
negative regulation of activated T cell proliferation At A Glance
| GO ID | GO:0046007 |
|---|---|
| GO term | negative regulation of activated T cell proliferation |
| Ontology | biological_process |
| Synonym | inhibition of activated T cell proliferation; downregulation of activated T cell proliferation; negative regulation of activated T-lymphocyte proliferation |
| Major function | Restrains the expansion of activated T cells to maintain immune homeostasis and peripheral tolerance |
| Biological context | Acts after TCR engagement and costimulation, integrating coinhibitory and phosphatase signals |
| Key regulators | CTLA4, GSK-3, HePTP, CD53, NFAT pathway components |
| Disease relevance | Autoimmunity, transplant rejection, cancer immunosuppression, chronic infection |
What Is GO:0046007?
GO:0046007 is defined by QuickGO as any process that stops, prevents, or reduces the rate or extent of activated T cell proliferation. In practical terms, it covers molecular events that act after T cell activation to restrain cell-cycle entry, promote cell-cycle arrest, or limit survival and expansion of activated T lymphocytes. It is a biological_process term that sits downstream of T cell activation and upstream of immune response resolution.
Why Is negative regulation of activated T cell proliferation Important in Cell Biology?
Negative regulation of activated T cell proliferation is important because unchecked T cell expansion causes immunopathology, while excessive restraint causes immunodeficiency or tumor immune evasion. Understanding this process provides mechanistic insight into how the immune system resolves responses and how tumors and pathogens exploit inhibitory pathways.
• Prevents autoimmunity by limiting expansion of self-reactive activated T cells.
• Controls transplant rejection by regulating alloreactive T cell expansion.
• Shapes antitumor immunity; tumors can exploit inhibitory pathways to suppress T cell proliferation.
• Limits immunopathology during chronic infection by restraining excessive T cell expansion.
• Provides targets for checkpoint blockade and autoimmune therapies.
• Integrates TCR, costimulatory, and cytokine signals into a single proliferative outcome.
• Involves phosphatases such as HePTP that directly dampen TCR signal transduction.
• Involves kinases such as GSK-3 that suppress IL-2 production and proliferation.
• Tetraspanin CD53 regulates CD45RO stability and function, affecting T cell responses.
• Provides a tractable process for CRISPR screens and functional genomics in primary T cells.
What Happens During negative regulation of activated T cell proliferation?
TCR activation and costimulation set the proliferative threshold
In simple terms: First, the T cell receives an activating signal, and the strength of that signal determines whether it will divide.
T cell activation requires engagement of the T cell receptor (TCR) by peptide-MHC and a costimulatory signal, classically through CD28. The intensity and duration of these signals set the threshold for entry into the cell cycle. Negative regulation of activated T cell proliferation acts on this threshold by raising the requirement for activation or by directly opposing the signaling cascades that drive proliferation.
Coinhibitory receptor engagement
In simple terms: Inhibitory receptors act like brakes that are applied after the T cell has already been switched on.
CTLA4 is a coinhibitory receptor that competes with CD28 for ligands and delivers inhibitory signals to activated T cells, thereby limiting their expansion. Engagement of CTLA4 after activation recruits phosphatases that attenuate TCR signaling, contributing directly to negative regulation of activated T cell proliferation.
Phosphatase-mediated signal attenuation
In simple terms: Enzymes called phosphatases remove phosphate groups from signaling proteins, turning the activation signal down.
Hematopoietic tyrosine phosphatase (HePTP) negatively regulates TCR signal transduction by dephosphorylating key signaling intermediates, thereby reducing the intensity of signals that drive proliferation. This phosphatase activity represents a direct molecular mechanism for negative regulation of activated T cell proliferation.
Kinase-mediated suppression of IL-2 and proliferation
In simple terms: Certain kinases act as negative regulators by blocking the production of growth factors that T cells need to divide.
GSK-3 is a serine/threonine kinase that negatively regulates T cell proliferation and interleukin-2 production. Inhibition of GSK-3 enhances T cell proliferation, indicating that its activity restrains activated T cell expansion under physiological conditions.
Calcium/NFAT signaling and tolerance
In simple terms: Calcium signals through NFAT can switch a T cell from activation to tolerance, reducing further proliferation.
Calcium/NFAT signaling regulates T cell tolerance and can promote anergy or exhaustion programs that limit activated T cell proliferation. The balance of NFAT isoforms and the strength of calcium flux determine whether activated T cells expand or become unresponsive.
Tetraspanin and CD45 regulation
In simple terms: Scaffolding proteins on the cell surface control how long activating receptors stay active.
Tetraspanin CD53 controls T cell immunity by regulating the stability, mobility, and function of CD45RO, a phosphatase that modulates TCR signaling. Loss of CD53 alters T cell responses, demonstrating that surface organizers can influence the negative regulation of activated T cell proliferation.
Key Genes Involved in GO:0046007 negative regulation of activated T cell proliferation
The following genes and proteins have been experimentally implicated in the negative regulation of activated T cell proliferation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTLA4 | Coinhibitory receptor that competes with CD28 and delivers inhibitory signals | Checkpoint blockade target; regulates peripheral tolerance |
| GSK3A/GSK3B | Serine/threonine kinases that suppress IL-2 production and T cell proliferation | Pharmacological target; negative regulator of T cell expansion |
| PTPN7 (HePTP) | Hematopoietic tyrosine phosphatase that attenuates TCR signal transduction | Direct negative regulator of TCR signaling |
| CD53 | Tetraspanin that regulates CD45RO stability, mobility, and function | Modulates T cell immunity and proliferation |
| NFATC1 | Calcium-regulated transcription factor involved in T cell tolerance and anergy | Central node in calcium/NFAT tolerance signaling |
| NFATC2 | Calcium-regulated transcription factor that can promote anergy programs | Modulates activation versus tolerance outcomes |
| CD28 | Costimulatory receptor that sets the activation threshold opposed by CTLA4 | Context for coinhibitory regulation |
| CD45 (PTPRC) | Receptor tyrosine phosphatase that regulates TCR signal strength | Target of CD53 regulation in T cells |
| RUNX2 | Transcription factor identified in a genome-wide screen as a regulator of T-cell commitment | Candidate regulator from CRISPR screening |
| IL2 | Growth factor whose production is suppressed by GSK-3 | Readout of negative regulation |
| ICAM1 | Adhesion molecule that modulates T-cell proliferation and cytotoxicity | Context-dependent modulator of T cell responses |
| CCL21 | Chemokine that modulates T-cell proliferation and cytotoxicity when immobilized | Microenvironmental regulator of T cell responses |
| TCR complex | Antigen receptor whose signal is attenuated by HePTP and phosphatases | Upstream input to negative regulation |
| Steroid receptor pathway | Regulates T cell apoptosis via TCR and steroid receptors | Context for survival versus proliferation decisions |
| Calcium/NFAT pathway | Signaling module that integrates TCR signals into tolerance programs | Core mechanism of negative regulation |
| CD45RO | Isoform of CD45 whose stability is controlled by CD53 | Modulates TCR signaling and proliferation |
How Is negative regulation of activated T cell proliferation Regulated?
Negative regulation of activated T cell proliferation is itself regulated at multiple levels. Calcium/NFAT signaling integrates TCR signal strength and can shift activated T cells toward tolerance or anergy, thereby reducing proliferation. Coinhibitory receptors such as CTLA4 are induced after activation and compete with CD28, raising the threshold for further expansion. Intracellular phosphatases such as HePTP directly dephosphorylate TCR signaling intermediates, providing a rapid brake on activation. Serine/threonine kinases such as GSK-3 suppress IL-2 production and proliferation, and their inhibition enhances T cell expansion. Surface organizers such as CD53 regulate CD45RO stability and mobility, indirectly tuning TCR signal strength. Together, these layers ensure that activated T cell proliferation is tightly controlled in time and magnitude.
negative regulation of activated T cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CTLA4 | Autoimmunity and transplant rejection | CTLA4 knockout or point-mutation T cell models |
| GSK3A/GSK3B | Autoimmunity and T cell hyperproliferation | GSK-3 knockout or inhibitor-treated T cell cultures |
| PTPN7 (HePTP) | T cell signaling dysregulation | HePTP knockout Jurkat or primary T cells |
| CD53 | Immunodeficiency and T cell response defects | CD53 knockout T cell lines and primary T cells |
| NFATC1/NFATC2 | Tolerance breakdown and autoimmunity | NFAT knockout or knock-in reporter T cells |
Autoimmunity and loss of tolerance
Failure of negative regulation of activated T cell proliferation can permit expansion of self-reactive T cells, contributing to autoimmune pathology. Calcium/NFAT signaling is a key pathway that enforces tolerance, and its dysregulation is linked to breakdown of peripheral tolerance. Coinhibitory pathways such as CTLA4 are critical for restraining autoreactive responses, and their dysfunction is associated with autoimmunity.
Cancer immunosuppression
Tumors can exploit inhibitory pathways that suppress activated T cell proliferation to evade immune destruction. Microenvironmental factors such as immobilized CCL21 and ICAM1 modulate T-cell proliferation and cytotoxicity, illustrating how the tumor niche can tune T cell expansion. Understanding these mechanisms informs the design of therapies that restore antitumor T cell proliferation.
Transplant rejection and alloreactivity
Alloreactive T cell expansion is a major driver of transplant rejection, and coinhibitory regulation by CTLA4 and CD28 sets the balance between rejection and tolerance. Modulating negative regulation of activated T cell proliferation is therefore a strategy for promoting graft acceptance.
Chronic infection and immunopathology
During chronic infection, excessive T cell proliferation can cause immunopathology, while insufficient restraint can lead to exhaustion. Calcium/NFAT signaling and phosphatase-mediated attenuation help balance these outcomes.
From negative regulation of activated T cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene enhance activated T cell proliferation? | CRISPR knockout in primary T cells or Jurkat cells |
| Does a specific phosphorylation site control negative regulation? | Point-mutation knock-in of phospho-dead or phospho-mimetic alleles |
| Does a disease-associated variant alter proliferation restraint? | Knock-in of the variant allele in T cell lines |
| Where and when is the regulator expressed during activation? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a negative regulator suppress proliferation? | Overexpression cell models in primary or immortalized T cells |
| Which genes are required for negative regulation in a genome-wide manner? | CRISPR library screening in activated T cells |
How to Study the negative regulation of activated T cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CFSE dilution | Cell division history of activated T cells | Quantifying negative regulation of proliferation |
| EdU incorporation | DNA synthesis in activated T cells | Measuring proliferation restraint |
| Phospho-Western blot | TCR signaling intermediate phosphorylation | Assessing HePTP-mediated attenuation |
| Calcium imaging | Intracellular calcium flux after TCR engagement | Linking calcium/NFAT to tolerance |
| NFAT luciferase reporter | NFAT transcriptional activity | Measuring tolerance versus activation programs |
| Flow cytometry | Surface expression of CD53, CD45RO, CTLA4 | Connecting surface phenotype to function |
| IL-2 ELISA | IL-2 production by activated T cells | Readout of GSK-3-mediated suppression |
| CRISPR library screen | Genome-wide requirement for negative regulation | Discovering novel regulators |
CRISPR knockout and functional proliferation assays
CRISPR knockout of candidate genes followed by CFSE dilution or EdU incorporation measures whether loss of a gene enhances or suppresses activated T cell proliferation. Genome-wide screens can identify novel regulators such as Runx2 in hematopoietic and T cell contexts.
Phospho-signaling and phosphatase assays
Western blotting for phosphorylated TCR signaling intermediates and phosphatase activity assays can quantify HePTP-mediated attenuation of TCR signals. These methods link molecular changes to proliferative outcomes.
Calcium flux and NFAT reporter assays
Calcium imaging and NFAT-dependent luciferase reporters measure the signaling module that controls tolerance versus activation in T cells. These assays help define how negative regulation is enforced at the transcriptional level.
Surface receptor and tetraspanin analysis
Flow cytometry and imaging of CD53, CD45RO, and coinhibitory receptors assess how surface organization modulates TCR signal strength and proliferation. These approaches connect membrane dynamics to functional outcomes.
How CRISPR Can Be Used to Study GO:0046007 negative regulation of activated T cell proliferation
Knockout
CRISPR knockout of candidate negative regulators such as PTPN7 or CD53 in T cell lines or primary T cells can test whether their loss enhances activated T cell proliferation. Genome-wide knockout screens can identify novel genes required for this process.
Point Mutation
Point-mutation knock-in of phospho-dead or phospho-mimetic residues in kinases such as GSK-3 or phosphatases such as HePTP can dissect which residues mediate negative regulation of activated T cell proliferation.
Knock-in
Knock-in of disease-associated variants in CTLA4 or other regulators can model how human polymorphisms alter the threshold for activated T cell proliferation. Tagged knock-in can also track protein localization and stability.
Overexpression
Overexpression of negative regulators such as GSK-3 or HePTP in T cell models can confirm sufficiency for suppressing activated T cell proliferation and IL-2 production.
How EDITGENE Supports negative regulation of activated T cell proliferation Research
Researchers studying negative regulation of activated T cell proliferation-related genes often need to determine whether a candidate gene is causally involved in restraining T cell expansion. EDITGENE provides CRISPR-based cell model services that enable loss-of-function, gain-of-function, and variant-specific experiments in T cell and immune cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of activated T cell proliferation research.
Frequently Asked Questions About negative regulation of activated T cell proliferation
What is negative regulation of activated T cell proliferation (GO:0046007)?
It is a biological process that stops, prevents, or reduces the rate or extent of proliferation of T cells that have already been activated, helping to maintain immune homeostasis and tolerance.
What genes are involved in negative regulation of activated T cell proliferation?
Key genes include CTLA4, GSK3A/GSK3B, PTPN7 (HePTP), CD53, and NFAT family members, all of which have been experimentally linked to restraining activated T cell expansion.
How does CTLA4 negatively regulate activated T cell proliferation?
CTLA4 competes with CD28 for ligands and delivers inhibitory signals that raise the threshold for T cell expansion after activation.
What is the role of GSK-3 in T cell proliferation?
GSK-3 is a serine/threonine kinase that negatively regulates T cell proliferation and interleukin-2 production; its inhibition enhances T cell expansion.
How does HePTP regulate TCR signaling?
HePTP is a hematopoietic tyrosine phosphatase that negatively regulates T cell antigen receptor signal transduction by dephosphorylating signaling intermediates.
What is the role of CD53 in T cell immunity?
CD53 is a tetraspanin that controls T cell immunity by regulating the stability, mobility, and function of CD45RO, thereby modulating TCR signaling.
How does calcium/NFAT signaling relate to T cell tolerance?
Calcium/NFAT signaling regulates T cell tolerance and can promote anergy programs that limit activated T cell proliferation.
Why is negative regulation of activated T cell proliferation important in cancer?
Tumors can exploit inhibitory pathways that suppress activated T cell proliferation to evade immune destruction, making this process relevant to immunotherapy.
What experimental models are used to study GO:0046007?
CRISPR knockout, point-mutation, knock-in, and overexpression T cell models, combined with proliferation assays and genome-wide screens, are commonly used.
How can CRISPR screening identify new regulators of activated T cell proliferation?
Genome-wide CRISPR knockout screens in activated T cells can reveal genes whose loss enhances or suppresses proliferation, as demonstrated by screens identifying regulators such as Runx2.
Conclusion
Negative regulation of activated T cell proliferation (GO:0046007) is a tightly controlled biological process that restrains T cell expansion after activation through coinhibitory receptors, phosphatases, kinases, and calcium/NFAT signaling. Its dysregulation contributes to autoimmunity, transplant rejection, and cancer immune evasion, making it a central topic in immunology research. CRISPR-based knockout, point-mutation, knock-in, overexpression, and library screening approaches provide powerful tools to dissect the genes and mechanisms underlying this process.
References
- 1. Meaker GA et al.. 2025. A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.. Blood 146(26):3188-3200 PMID: 40961240
- 2. Baine I et al.. 2009. Regulation of T-cell tolerance by calcium/NFAT signaling.. Immunol Rev 231(1):225-40 PMID: 19754900
- 3. Ohteki T et al.. 2000. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3.. J Exp Med 192(1):99-104 PMID: 10880530
- 4. Noel PJ et al.. 1996. Regulation of T cell activation by CD28 and CTLA4.. Adv Exp Med Biol 406:209-17 PMID: 8910687
- 5. Iwata M et al.. 1996. Regulation of T cell apoptosis via T cell receptors and steroid receptors.. Stem Cells 14(6):632-41 PMID: 8948021
- 6. Dunlock VE et al.. 2022. Tetraspanin CD53 controls T cell immunity through regulation of CD45RO stability, mobility, and function.. Cell Rep 39(13):111006 PMID: 35767951
- 7. Yado S et al.. 2024. Molecular mechanisms underlying the modulation of T-cell proliferation and cytotoxicity by immobilized CCL21 and ICAM1.. J Immunother Cancer 12(6) PMID: 38866588
- 8. Saxena M et al.. 1998. Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP).. J Biol Chem 273(25):15340-4 PMID: 9624114
